CME credits: 0.25

Valid until: 02-12-2026

Claim your CME credit at https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/

In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The discussion addresses key clinical considerations for transitioning between dopaminergic and muscarinic therapies, including cholinergic burden and cross-titration timing. This expert dialogue provides relevant guidance for clinicians aiming to incorporate muscarinic therapies into personalized treatment plans for schizophrenia.

=